therap study: lu-psma vs. cabazitaxel #asco20 #anzup
Published 4 years ago • 2.4K plays • Length 11:23Download video MP4
Download video MP3
Similar videos
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
4:08
lu-177 psma-617 versus vs cabazitaxel: therap trial @ snmmi 2021
-
9:29
anzup therap study @ asco gu 2021
-
2:56
therap: lupsma versus cabazitaxel for prostate cancer
-
2:37
therap: cabazitaxel versus 177lu-psma-617 for mcrpc
-
1:27:40
pcf - prostic - anzup global knowledge exchange webinar on the therap study
-
5:59
lupsma vs cabazitaxel in metastatic castration-resistant prostate cancer progressing after docet...
-
8:58
ascu gu 2022: imaging biomarkers in the anzup therap study
-
4:00
therap trial and effectiveness of lu-psma-617
-
5:51
lupsma vs cabazitaxel for metastatic castration-resistant prostate cancer
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
10:47
therap trial
-
8:11
asco: lupsma vs cabazitaxel for castration-resistant prostate cancer
-
0:51
therap trial of 177lu-psma-617 review | david vanderweele, md | asco22 prostate cancer updates
-
4:46
lutetium-177–psma-617: appropriate and potential off-label utility
-
3:16
updated therap data further support lupsma for mcrpc | michael hofman
-
14:37
lupsma: the newest treatment class for advanced prostate cancer
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc